8-K - MoonLake Immunotherapeutics | StockGist

Current Report Details

Event Type

Material Agreement+5 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, ent

Material Agreement

$25.0M$400.0M$500.0M$75.0M

2.02

and the press release attached here to as Exhibit 99.1, insofar as they disclose information regarding the Company’s results of operations and financial conditi

Financial Results

2.03

. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. O

Financing

Company on any matter relating to the Company

7.01

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang

Regulation Fd

8.01

Other Events. On February 22, 2026, the Company issued a press release announcing topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiog

Other Event

$394.0M

9.01

. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED FEBRUARY 22, 2026